Welcome to our dedicated page for R1 Rcm news (Ticker: RCM), a resource for investors and traders seeking the latest updates and insights on R1 Rcm stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect R1 Rcm's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of R1 Rcm's position in the market.
R1 RCM has launched R1 Entri™, an intelligent patient engagement solution, at the HIMSS21 Global Health Conference in Las Vegas. This tool enhances patient experiences by allowing users to search, book, register, and pay for care seamlessly on any device. By integrating revenue cycle touchpoints, Entri optimizes operational efficiency and financial performance for healthcare providers. The initiative reflects R1's commitment to evolving the revenue cycle beyond billing and coding, focusing on improved patient-centric technology.
R1 RCM reported second quarter 2021 results with revenues of $353.4 million, marking a 12.3% increase year-over-year. GAAP net income rose to $18.4 million, up 21.9%, while adjusted EBITDA reached $78.8 million, a 20.7% rise. The company raised its 2021 guidance, projecting revenues between $1,460 million and $1,480 million, GAAP operating income of $135 million to $145 million, and adjusted EBITDA of $330 million to $340 million. Management emphasized strong operational execution and continued investment in technology.
R1 RCM Inc. (NASDAQ: RCM) has appointed Jay Sreedharan as its first chief technology and digital officer to enhance its technological capabilities and digital solutions.
Sreedharan, with over 20 years of experience in technology innovations, previously held key positions at MGM Resorts and Starbucks. He will be pivotal in driving R1's digital transformation strategy, focusing on product development, engineering, and potential digital M&A activities. This leadership change aims to strengthen R1's market position and improve healthcare access for patients.
R1 RCM Inc. (NASDAQ: RCM) will release its financial results for the quarter ending June 30, 2021, before market open on August 3, 2021. Following this, R1's management will host a conference call at 8:00 a.m. ET to discuss the results and future outlook. Interested participants can join via phone or access a live webcast on the company’s investor relations website. R1 is a leader in technology-driven solutions designed to enhance patient experience and healthcare financial performance.
R1 RCM (NASDAQ:RCM) has completed its acquisition of VisitPay, enhancing its technology-driven solutions for healthcare providers. This strategic move integrates VisitPay's digital payment platform with R1's patient access solutions, offering patients a seamless financial journey. This includes improved transparency of healthcare costs and personalized payment options. The acquisition positions R1 to deliver a superior billing experience, potentially increasing patient satisfaction and revenue for healthcare partners.
R1 RCM announced a secondary offering of 15 million shares priced at $22.50 each by existing stockholders, including TCP-ASC and CEO Joseph Flanagan. The offering is set to close on June 1, 2021, pending customary conditions. R1 RCM will not benefit from the proceeds, which are going to the selling stockholders. An additional option for underwriters to buy 2.25 million shares exists. The offering is being conducted under an effective shelf registration statement filed with the SEC.
R1 RCM announced a secondary offering of 15,000,000 shares of its common stock, conducted by selling stockholders TCP-ASC and CEO Joseph Flanagan. The underwriters, including Barclays and J.P. Morgan, hold a 30-day option for an additional 2,250,000 shares. R1 RCM will not receive proceeds from this sale, and this offering is made under an existing registration statement. The company emphasizes its commitment to enhancing patient experience and financial performance in healthcare.
R1 RCM (NASDAQ:RCM) has secured a partnership with Mednax (NYSE:MD) to provide enterprise revenue cycle management services. This collaboration is anticipated to enhance Mednax's patient experience and streamline its clinical and financial operations.
R1's technology-driven solutions aim to reduce operating costs and improve revenue cycle efficiency. Mednax's CEO emphasized that this partnership will allow their clinicians to focus on patient care while benefiting from R1's technological expertise.
R1 RCM Inc (NASDAQ: RCM) reported strong Q1 2021 financial results, with revenue reaching $342.6 million, a 6.9% increase year-over-year. GAAP net income increased to $25.8 million, up 41.8% compared to the previous year, while Adjusted EBITDA rose to $80.4 million, marking a 30.5% increase. The company anticipates full-year revenue between $1,410 million and $1,460 million and an Adjusted EBITDA of $315 million to $330 million.
Management highlighted strong execution and digitization investments as key factors in their performance.
R1 RCM announced its acquisition of VisitPay for approximately $300 million in cash to enhance digital patient payment solutions across healthcare settings. The deal, expected to close in Q3 2021, aims to improve patient satisfaction and streamline billing processes through VisitPay’s cloud-based platform. The transaction is set to provide a tax benefit of about $40 million, reducing the effective purchase price to $260 million. This strategic move will position R1 as a leader in healthcare payment solutions.